Carotid Artery Diseases, Coronary Artery Disease, Diabetes Mellitus, Type 2
Conditions
Keywords
Dapagliflozin, Glibenclamide, Endothelial Function, Vascular Endothelial Cells, Flow Mediated Dilation
Brief summary
Background Endothelial dysfunction is one of the early events in atherosclerotic plaque development. It is characterized by an increased ratio of substances with vasoconstrictive, pro-thrombotic, and proliferative properties over substances with vasolidatory, antithrombogenic and antimitogenic properties. Endothelial dysfunction is also associated with high-risk patients with coronary artery disease. Hyperglycemia, obesity, hypertension and fat mass also impair the endothelium by increasing the expression of cytokines, inflammatory markers and vascular markers. Hypothesis Administration of dapagliflozin in addition to metformin background with clinical or subclinical cardiovascular atherosclerotic disease improves endothelial function when compared to those using glibenclamide in addition to metformin. Objectives Evaluate the effect of dapagliflozin vs glibenclamide on a metformin background on endothelial function in patients with clinical or subclinical cardiovascular atherosclerotic disease and poorly controlled diabetes. Enpoints Prymary Change in flow mediated dilation (FMD) and its related endpoint (FMD post reperfusion lesion) between the randomization visit and over 12 weeks of treatment. Secondary Change in plasma nitric oxide, isoprostane, ICAM-1, VCAM-1, ET-1, leptin, adiponectin, C-reactive protein, TNF- α, interleukin-6, interleukin-2, weight and body composition (% of fat mass and % free fat mass) at the randomization visit and over 12 weeks of treatment. 3 Design Randomized, parallel-group, comparative, prospective clinical study. The study is divided in two phases: Run-in and Randomization. In the former phase, which must have the maximum period of 16 weeks, patients will visit the outpatient to adjust metformin and blood pressure medications. After run-in phase, patients that fulfill inclusion criteria will perform an ambulatory blood pressure monitoring (ABPM) in order to asses BP; body composition will be assessed by dual x-ray absorptiometry (DXA); endothelial function as assessed by flow mediated dilation and vascular cytokines. Patients will by randomized to dapagliflozin or glibenclamide on a metformin background. After 12 weeks, the ABPM, DXA and endothelial function will be assessed.
Interventions
DRUGDapagliflozin 10 mg
Dapagliflozin 10 mg in addition to Metformin 1500 mg/day
DRUGGlibenclamide 5 mg
Glibenclamide 5 mg in addition to Metformin 1500 mg/day
Sponsors
AstraZeneca
University of Campinas, Brazil
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
40 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
(i) chronic coronary artery disease as shown by angiogram or subclinical artery disease diagnosed by the presence of carotid atherosclerotic plaque or carotid Intima-Media Thickness (cIMT) ≥ 1mm; (ii) T2DM using up to two oral hypoglycemic agents; (iii) inadequate glycemic control (HbA1c ≥ 7%);
Exclusion criteria
(i) HbA1c \> 9%; (ii) contraindications to metformin use (Cr Clearance \<60 ml/min, Cr\> 1.5 mg/dL in men and\> 1.4 mg/dl in women, liver failure - AST or ALT\> 3x upper normal limit or other conditions that might increase the risk of lactic acidosis); (vi) at the time of randomization, patient who is not on metformin XR 1500 mg/day monotherapy for at least 12 weeks; (vii) patients who spend more than 16 weeks to adjust metformin before randomization; (viii) BP ≥ 140 x 90 after 16 weeks of anti-hypertensive medication adjustment; (iii) hospitalization for unstable angina or acute myocardial infarction within 2 months prior to enrolment; (iv) acute stroke or transient ischemic attack (TIA) within two months prior to enrolment; (v) less than two months post coronary artery revascularization; (ix) patients with FMD \<2% at the time of randomization; (x) triglycerides \> 500 mg/dL; (xi) known allergy to any of the study drugs; (xii) patients with severe coronary artery disease and heart failure; (xiii) systemic vasculitis; (xiv) conditions that lead to systemic inflammation; (xv) patients using rosiglitazone; (xvi) polyuria, polydipsia, weight loss, or others clinical signs of volume depletion; (xvii) those who refuse to participate or sign the Statement of Informed Consent; (xviii) pregnancy or women during reproductive age; (xix) breastfeeding women; (xx) history of gastrointestinal disorders that may interfere with the absorption of study medication; (xxi) patients who are participating in other clinical studies or whose participation ended less than six months ago.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in flow mediated dilation (FMD) and its related endpoint (FMD post reperfusion lesion) | 12 weeks |
Secondary
| Measure | Time frame |
|---|---|
| Change in plasma Endothelin-1 (ET-1) | 12 weeks |
| Change in plasma interleukin-6 | 12 weeks |
| Change in plasma interleukin-2 | 12 weeks |
| Change in weight | 12 weeks |
| Change in body composition (% of fat mass and % free fat mass) | 12 weeks |
| Change in plasma nitric oxide | 12 weeks |
| Change in plasma isoprostane | 12 weeks |
| Change in plasma nitric oxide after reperfusion injury. | 12 weeks |
| Change in plasma isoprostane after reperfusion injury. | 12 weeks |
| Change in plasma Intercellular Adhesion Molecule 1(ICAM-1) | 12 weeks |
| Change in plasma Vascular Cell Adhesion Molecule 1 (VCAM-1) | 12 weeks |
| Change in plasma Leptin | 12 weeks |
| Change in plasma Adiponectin | 12 weeks |
| Change in plasma C-reactive protein (CRP) | 12 weeks |
| Change in plasma Tumor Necrosis Factor alpha (TNF-α) | 12 weeks |
Other
| Measure | Time frame |
|---|---|
| Change in Mean Arterial Blood Pressure | 12 weeks |
| Change in Waist Circumference | 12 weeks |
| Change in Glycated Hemoglobin | 12 weeks |
| Change in Systolic Blood Pressure | 12 weeks |
Countries
Brazil
Outcome results
None listed